TERAZOL 7
LOE ApproachingNDAVAGINALCREAM
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TERAZOL 7 is a vaginal cream antifungal indicated for treating vulvovaginal candidiasis (yeast infections). The product is a small-molecule azole antifungal applied topically to the vaginal site for local therapeutic effect.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand teams should expect defensive positioning and potential team rightsizing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TERAZOL 7 offers limited career advancement due to approaching LOE and zero linked job openings. Roles on this brand are likely focused on cost management, generic defense, and portfolio transition rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on TERAZOL 7 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.